Richard Lafayette, MD, FACP

Richard Lafayette, MD, FACP, is professor of medicine, nephrology, and director, Glomerular Disease Center, Stanford University Medical Center, and Vanrafia ALIGN study investigator and steering committee member.

Articles by Richard Lafayette, MD, FACP

Atrasentan Has Promising Long-Term Potential in IgA Nephropathy: Richard Lafayette, MD, FACP

ByMaggie L. Shaw,Richard Lafayette, MD, FACP

June 24th 2025

Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how patients may need to adjust should final ALIGN trial data fail to show a clinical benefit of atrasentan.

Richard Lafayette, MD, FACP, Stanford University Medical Center

New Hope for IgA Nephropathy With Atrasentan Approval: Richard Lafayette, MD, FACP

ByMaggie L. Shaw,Richard Lafayette, MD, FACP

April 11th 2025

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month for proteinuria reduction.

Richard Lafayette, MD, FACP

Articles by Richard Lafayette, MD, FACP

Atrasentan Has Promising Long-Term Potential in IgA Nephropathy: Richard Lafayette, MD, FACP

New Hope for IgA Nephropathy With Atrasentan Approval: Richard Lafayette, MD, FACP

Latest Updated Articles

Trending on AJMC

Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal

Sexual Dysfunction From Cancer Is Widespread—and Many Don’t Know That Before Treatment, Data Show

Enzalutamide Combo Improves OS in Prostate Cancer Without Sacrificing Quality of Life: Stephen Freedland, MD

The Growing ADC Landscape in TNBC Brings Questions, Opportunities: Rebecca Dent, MD, MSc

Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis